Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines worldwide. With a market cap of $10.6 billion, the company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development.

Companies valued at $10 billion or more are generally described as "large-cap stocks", and Moderna fits this criterion perfectly. The company is also expanding its pipeline to include treatments for cancer, rare diseases, and autoimmune conditions, reflecting its broader commitment to revolutionizing medicine through cutting-edge mRNA science.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.